防治ASCVD的调脂治疗新靶点:血管生成素样蛋白3  

Angiopoietin-like protein 3:a novel target of lipid-lowering therapy in ASCVD

作　　者：李勇 谢坤 LI Yong;XIE Kun(Department of Cardiology,Huashan Hospital Affiliated to Fudan University,Shanghai,200040,China)

机构地区：[1]复旦大学附属华山医院心内科,上海200040

出　　处：《临床心血管病杂志》2021年第9期783-786,共4页Journal of Clinical Cardiology

摘　　要：血管生成素样蛋白(ANGPTL3)是继PCSK9抑制剂之后,调脂领域新的研究靶点。目前针对这一新兴靶点的治疗方式多样,除单克隆抗体外,还包括反义寡核苷酸、RNA干扰以及基因编辑疗法,在数个相关临床试验中,已展现出突出疗效,其未来发展值得关注。Angiopoietin-like protein(ANGPTL3) is a new research hotspot in the field of lipid regulation after PCSK9 inhibitors. In several related clinical trials, it has demonstrated the outstanding efficacy. There are various treatments for this emerging target. In addition to monoclonal antibodies, they also include antisense oligonucleotides, RNAi, and gene editing therapies. The future of ANGPTL3 is worthy of attention.

关 键 词：动脉粥样硬化性心血管疾病 血管生成素样蛋白3 高脂血症 调脂治疗 

分 类 号：R543[医药卫生—心血管疾病]